Molecular Basis of Substrate Translocation in the Drug/H+ Antiporter 1 Family
药物/H 逆向转运蛋白 1 家族底物易位的分子基础
基本信息
- 批准号:10414517
- 负责人:
- 金额:$ 32.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-06-15 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:AlcoholismAmino AcidsAntimicrobial ResistanceBindingBiochemicalBiologicalBipolar DisorderBrainCationsCell membraneCellsChemical StructureClinicalCommunicable DiseasesComplexCoupledCouplesDataDevelopmentDrug Binding SiteDrug EffluxDrug ModelingsEscherichia coliFamilyGilles de la Tourette syndromeGoalsHumanHuntington DiseaseInfectionIntegral Membrane ProteinLeadLigandsLightMajor Depressive DisorderMalignant NeoplasmsMediatingMembraneMembrane ProteinsMental DepressionModelingMolecularMovementMulti-Drug ResistanceMutagenesisMutateNeuromodulatorNeurotoxinsNeurotransmittersParkinson DiseasePathogenicityPatientsPharmaceutical PreparationsPhysiologicalPolyaminesProcessProtein Export PathwayProteinsPublishingReportingResearchRoentgen RaysSchizophreniaSiteStructureTherapeuticTransmembrane TransportTreatment EfficacyVariantWorkalcoholism therapyantimicrobialantiportantiporterautism spectrum disorderbaseclinically relevantdeprotonationeffective therapyexperienceinhibitorinsightmembrane modelmicroorganismmonoaminemulti drug transportermutantnervous system disorderneuropsychiatryneurotransmissionnovel strategiesnovel therapeutic interventionoverexpressionpathogenic bacteriaprotonationsolutestructural biologytargeted treatmenttherapeutic targetunpublished worksvesicle transport
项目摘要
Molecular Basis of Substrate Translocation in the Drug/H+ Antiporter 1 Family
Summary
Integral membrane proteins known as multidrug transporters extrude therapeutic drugs of diverse
chemical structures across cell membranes, impeding the treatment of human cancers, infectious
diseases, and neurological disorders. Currently we lack a deep and mechanistic understanding of how
these proteins export drugs or how they can be thwarted. We will study the structure and mechanism
of a model multidrug transporter, MdfA from Escherichia coli, which couples the influx of H+ to the
efflux of various antimicrobials and belongs to the ubiquitous Drug/H+ Antiporter 1 (DHA1) family.
MdfA orthologues are present in many pathogenic microorganisms, and the overexpression of E. coli
MdfA can lead to antimicrobial resistance in clinical patients. Thus, MdfA represents an important
target for therapeutic exploitation to overcome multidrug resistance. Furthermore, the SLC18
antiporters, which are the human counterparts of MdfA in the DHA1 family, conduct the H+-dependent
vesicular transport of monoamine neurotransmitters, polyamine neuromodulators, and neurotoxins.
The human SLC18 antiporters are essential for brain function and promising therapeutic targets for
battling alcoholism, autism spectrum disorders, bipolar disorder, Huntington disease, major depressive
disorder, Parkinson’s disease, schizophrenia, and Tourette syndrome. Our long-term objective is to
understand how the DHA1 multidrug transporters and human SLC18 antiporters translocate their
substrates and how their function can be modulated for potential therapeutic benefit. Notably, prior
biochemical studies have suggested that MdfA translocates certain substrates via a non-canonical
mechanism. Drawing upon these data and our experience in membrane protein structural biology, we
will accomplish two aims: (1) to elucidate the molecular basis for simultaneous translocation of two
mono-cationic substrates by a DHA1; (2) to reveal the structural mechanism for non-canonical, DHA1-
mediated extrusion of di-cationic therapeutics. By combining crystallographic and biochemical studies,
we will acquire new insights into how a DHA1 translocates two substrates concurrently, how a DHA1
inhibitor differs from the substrate, and how a DHA1 exports a therapeutic drug in two consecutive and
yet different deprotonation/protonation cycles. The new conceptual framework and DHA1 structures
obtained from this study will serve as a stepping-stone toward devising novel strategies to evade or
inhibit the clinically relevant multidrug transporters, which may rescue therapeutic efficacy against
multidrug-resistant cells and halt the spread of untreatable infections. Furthermore, our work will offer
a springboard for the mechanistic studies of human SLC18 antiporters, which will shed new light on
how they utilize the electrochemical H+ gradient to translocate monoamine neurotransmitters,
neurotoxins, or polyamine neuromodulators, across vesicular membranes.
药物/H+逆向转运蛋白1家族底物转运的分子基础
总结
被称为多药转运蛋白的整合膜蛋白挤出多种治疗药物,
细胞膜上的化学结构,阻碍人类癌症的治疗,传染性
疾病和神经系统疾病。目前,我们缺乏一个深刻的和机械的理解,
这些蛋白质输出药物或如何阻止它们。我们将研究其结构和机制
来自大肠杆菌的模型多药物转运蛋白MdfA,其将H+的流入与
它是多种抗菌剂的外排,属于普遍存在的药物/H+反向转运蛋白1(DHA 1)家族。
MdfA同源基因存在于许多病原微生物中,并且E.杆菌
MdfA可导致临床患者的抗菌药物耐药性。因此,MdfA代表重要的
用于治疗开发以克服多药耐药性靶点。此外,SLC 18
反向转运蛋白是DHA 1家族中MdfA的人类对应物,
单胺神经递质、多胺神经调质和神经毒素的囊泡转运。
人SLC 18反向转运蛋白是脑功能所必需的,并且是有希望的治疗靶点。
与酗酒、自闭症谱系障碍、躁郁症、亨廷顿病、重度抑郁症作斗争
帕金森氏症、精神分裂症和抽动秽语综合征。我们长远的目标是
了解DHA 1多药物转运蛋白和人SLC 18反向转运蛋白如何转运
底物以及如何调节它们的功能以获得潜在的治疗益处。值得注意的是,
生物化学研究表明,MdfA通过非典型的
机制利用这些数据和我们在膜蛋白结构生物学方面的经验,我们
将实现两个目标:(1)阐明两个同时易位的分子基础
单阳离子底物的DHA 1;(2)揭示非典型的结构机制,DHA 1-
介导双阳离子治疗剂的挤出。通过结合晶体学和生物化学研究,
我们将获得新的见解,如何DHA 1易位两个基板同时,如何DHA 1
抑制剂与底物不同,以及DHA 1如何在两个连续的
还有不同的去质子化/质子化循环。新的概念框架和DHA 1结构
从这项研究中获得的信息将作为设计新策略的垫脚石,
抑制临床相关的多药转运蛋白,这可能会挽救对
多药耐药细胞,并阻止无法治愈的感染的传播。此外,我们的工作将提供
人类SLC 18反向转运蛋白的机制研究的跳板,这将揭示新的光
它们如何利用电化学H+梯度来转运单胺神经递质,
神经毒素或多胺神经调节剂,穿过囊泡膜。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Min Lu其他文献
Min Lu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Min Lu', 18)}}的其他基金
Molecular Basis of Substrate Translocation in the Drug/H+ Antiporter 1 Family
药物/H 逆向转运蛋白 1 家族底物易位的分子基础
- 批准号:
10644018 - 财政年份:2022
- 资助金额:
$ 32.76万 - 项目类别:
Development of novel small-molecule inhibitors of HIV-1 fusion as microbicides
作为杀微生物剂的新型 HIV-1 融合小分子抑制剂的开发
- 批准号:
8892301 - 财政年份:2014
- 资助金额:
$ 32.76万 - 项目类别:
Engineered Envelope Glycoprotein Trimers for HIV-1 Vaccine Immunogens
用于 HIV-1 疫苗免疫原的工程包膜糖蛋白三聚体
- 批准号:
8743611 - 财政年份:2014
- 资助金额:
$ 32.76万 - 项目类别:
Small-molecule inhibitors of gp41-mediated fusion as HIV-1 topical microbicides
gp41 介导融合的小分子抑制剂作为 HIV-1 局部杀菌剂
- 批准号:
8743614 - 财政年份:2014
- 资助金额:
$ 32.76万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8743609 - 财政年份:2014
- 资助金额:
$ 32.76万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8607113 - 财政年份:2011
- 资助金额:
$ 32.76万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8230476 - 财政年份:2011
- 资助金额:
$ 32.76万 - 项目类别:
Development of an HIV-1 entry inhibitor pre-drug as a microbicide
开发作为杀微生物剂的 HIV-1 进入抑制剂前药
- 批准号:
8112130 - 财政年份:2011
- 资助金额:
$ 32.76万 - 项目类别:
The Role of Scavenger Receptor gp340 in Mucosal HIV-1 Transmission and Inhibition
清道夫受体 gp340 在粘膜 HIV-1 传播和抑制中的作用
- 批准号:
8704604 - 财政年份:2011
- 资助金额:
$ 32.76万 - 项目类别:
Development of an HIV-1 entry inhibitor pre-drug as a microbicide
开发作为杀微生物剂的 HIV-1 进入抑制剂前药
- 批准号:
8262674 - 财政年份:2011
- 资助金额:
$ 32.76万 - 项目类别:
相似海外基金
Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
- 批准号:
BB/Y006380/1 - 财政年份:2024
- 资助金额:
$ 32.76万 - 项目类别:
Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
- 批准号:
24K17112 - 财政年份:2024
- 资助金额:
$ 32.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
- 批准号:
2300890 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Continuing Grant
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
- 批准号:
23K06918 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
- 批准号:
23K05758 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
- 批准号:
23K04668 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
- 批准号:
2888395 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Studentship
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
- 批准号:
10761044 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
- 批准号:
10728925 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
- 批准号:
10757309 - 财政年份:2023
- 资助金额:
$ 32.76万 - 项目类别:














{{item.name}}会员




